ClinicalTrials.gov
ClinicalTrials.gov Menu

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions (ENDEAVOR IV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00217269
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : April 20, 2012
Sponsor:
Information provided by (Responsible Party):
Medtronic Vascular

Brief Summary:
The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.5-3.5 mm.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Coronary Artery Stenting Not Applicable

Detailed Description:
The ENDEAVOR IV Trial is a prospective, multi-center, randomized, two-arm, single-blind trial that will enroll a total of 1,548 patients at up to 80 sites in the US. The ENDEAVOR IV Trial will assess if the Endeavor stent is equivalent in safety and efficacy to the Taxus stent for the treatment of single de novo lesions in native coronary arteries with a RVD of 2.5-3.5 mm.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1548 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Study Start Date : April 2005
Actual Primary Completion Date : March 2007
Actual Study Completion Date : July 2011

Arm Intervention/treatment
Experimental: 1
Endeavor Drug Eluting Stent
Device: Coronary Artery Stenting
Endeavor Drug eluting stent
Active Comparator: 2
Taxus Drug Eluting Stent
Device: Coronary Artery Stenting
Taxus Drug Eluting Stent



Primary Outcome Measures :
  1. Target vessel failure (TVF) rate [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Angiographic parameters (in-stent and in-segment) including: percent diameter stenosis (%DS) [ Time Frame: 8 months ]
  2. Late lumen loss (in-segment late lumen loss is a powered secondary endpoint) [ Time Frame: 9 months ]
  3. Late loss index [ Time Frame: 9 months ]
  4. Angiographic binary restenosis (ABR) rate [ Time Frame: 9 months ]
  5. Minimum luminal diameter (MLD) [ Time Frame: 9 months ]
  6. Major adverse cardiac event (MACE) rate [ Time Frame: 30 days, 6, 9, and 12 months ]
  7. Neointimal hyperplastic volume and percent volume obstruction (%VO) as measured by intravascular ultrasound (IVUS) [ Time Frame: 8 months ]
  8. Target site revascularization (TSR) rate and clinically-driven TSR rate [ Time Frame: 9 months ]
  9. Target vessel revascularization (TVR) rate and clinically-driven TVR rate [ Time Frame: 9 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study.
  • The patient is an acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG) surgery.
  • Female patients of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
  • The patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical site.
  • The patient agrees to return to the same research facility for all required post-procedure follow-up visits.

Exclusion Criteria:

  • A known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, ticlopidine or clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings (e.g., Phosphorylcholine or Translute), or a sensitivity to contrast media, which cannot be adequately pre-medicated.
  • History of an allergic reaction or significant sensitivity to drugs such as ABT-578, rapamycin, tacrolimus, everolimus, or any other analogue or derivative.
  • History of an allergic reaction or significant sensitivity to paclitaxel or drugs in similar class.
  • A platelet count < 100,000 cells/mm³ or > 700,000 cells/mm³, or a white blood cell (WBC) count < 3,000 cells/mm³.
  • A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
  • Evidence of an acute MI within 72 hours of the intended index procedure (defined as: QWMI or non-Q wave myocardial infarction (NQWMI) having CK enzymes > 2X the upper laboratory normal with the presence of a CK-MB elevated above the Institution's upper limit of normal).
  • Previous PCI of the target vessel within 9 months pre-procedure.
  • Planned PCI of any vessel within 30 days post-procedure.
  • During the index procedure, the target lesion requires treatment with a device other than PTCA prior to stent placement (including but not limited to, cutting balloon, any atherectomy, any laser, thrombectomy, etc.).
  • History of a stroke or transient ischemic attack (TIA) within the prior 6 months.
  • Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.
  • History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • Any previous or planned treatment of the target vessel with anti-restenotic therapies including, but not limited to brachytherapy.
  • Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.
  • Documented left ventricular ejection fraction (LVEF) < 30% at most recent evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00217269


Locations
United States, New York
New York-Presbyterian Hospital/Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Medtronic Vascular
Investigators
Principal Investigator: Martin B. Leon, M.D. Columbia University College of Physicians & Surgeons

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Medtronic Vascular
ClinicalTrials.gov Identifier: NCT00217269     History of Changes
Other Study ID Numbers: IP060
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: April 20, 2012
Last Verified: April 2012

Keywords provided by Medtronic Vascular:
Restenosis

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases